Loading...
XNAS
VIVS
Market cap6mUSD
Sep 17, Last price  
3.64USD
1D
-5.21%
1Q
158.16%
Jan 2017
-99.55%
IPO
-99.69%
Name

Organovo Holdings Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
45.50
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-25.73%
Rev. gr., 5y
-42.01%
Revenues
144k
+32.11%
01,197,000379,000571,0001,483,0004,230,0004,603,0003,091,0002,196,00001,500,000370,000109,000144,000
Net income
-2m
L-83.04%
-147,817-43,553,000-25,848,000-30,082,000-38,575,000-38,447,000-34,803,000-26,635,000-18,710,000-16,826,000-11,448,000-17,259,000-14,671,000-2,488,000
CFO
-9m
L-35.43%
-109,425-9,693,000-15,561,000-19,601,000-29,368,000-29,185,000-28,857,000-20,375,000-14,882,000-13,323,000-8,453,000-12,408,000-14,653,000-9,461,000

Profile

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
URL
https://organovo.com/
IPO date
Aug 02, 2013
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
144
32.11%
109
-70.54%
370
-75.33%
Cost of revenue
12,721
15,142
18,266
Unusual Expense (Income)
NOPBT
(12,577)
(15,033)
(17,896)
NOPBT Margin
Operating Taxes
2
2
2
Tax Rate
NOPAT
(12,579)
(15,035)
(17,898)
Net income
(2,488)
-83.04%
(14,671)
-15.00%
(17,259)
50.76%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,847
1,437
BB yield
-269.85%
-15.26%
Debt
Debt current
521
1,012
492
Long-term debt
1,363
2,282
3,118
Deferred revenue
Other long-term liabilities
Net debt
(9,428)
393
(12,540)
Cash flow
Cash from operating activities
(9,461)
(14,653)
(12,408)
CAPEX
(13)
(42)
(396)
Cash from investing activities
9,025
816
(966)
Cash from financing activities
8,847
1,437
FCF
(11,710)
(14,583)
(17,690)
Balance
Cash
11,312
2,901
16,007
Long term investments
143
Excess cash
11,305
2,896
16,132
Stockholders' equity
(342,155)
(339,659)
(324,987)
Invested Capital
353,589
345,160
342,121
ROIC
ROCE
EV
Common stock shares outstanding
1,464
9,145
8,713
Price
2.24
117.48%
1.03
-52.97%
2.19
-41.76%
Market cap
3,278
-65.19%
9,419
-50.64%
19,082
-41.69%
EV
(6,150)
9,812
6,542
EBITDA
(12,311)
(14,753)
(17,603)
EV/EBITDA
0.50
Interest
10
470
Interest/NOPBT